Minimal Residue Disease Testing Market Scope And Analysis

  • Report Code : TIPRE00039104
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Ambito e analisi del mercato dei test sulle malattie a residui minimi dal 2021 al 2031

Buy Now

Minimal Residue Disease Testing Market Report Minimal Residue Disease Testing Market Size and Share Minimal Residue Disease Testing Market Scope and Analysis

Minimal Residue Disease Testing Market Report Scope

Report Attribute Details
Market size in 2023 US$ 3.55 Billion
Market Size by 2031 US$ 8.94 Billion
Global CAGR (2023 - 2031) 12.24%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Tecnica
  • citometria a flusso
  • PCR
  • NGS
  • altre
By Tipo di cancro
  • leucemia
  • linfoma
  • tumori solidi
  • mieloma multiplo
By Utente finale
  • ospedali
  • cliniche specialistiche
  • laboratori diagnostici
  • altri
Regions and Countries Covered Nord America
  • Stati Uniti
  • Canada
  • Messico
Asia Pacifico
  • Cina
  • Giappone
  • Corea del Sud
  • India
  • Australia
  • resto delAsia Pacifico
Europa
  • Germania
  • Francia
  • Regno Unito
  • Italia
  • Russia
  • resto Europa
Medio Oriente e Africa
  • Arabia Saudita
  • Emirati Arabi Uniti
  • Sudafrica
  • Resto del Medio Oriente e Africa
America centrale e meridionale
  • Brasile
  • Argentina
  • Resto delAmerica centrale e meridionale
Market leaders and key company profiles
  • Adaptive Biotechnologies,
  • Natera,
  • Bio-Rad Laboratories,
  • F-Hoffmann La Roche Ltd,
  • Guardant Health,
  • LabCorp,
  • Sysmex Corporation,
  • ARUP Laboratories,
  • Invivoscribe, Inc.,
  • NeoGenomics Laboratories, Inc.,